Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
242 Leser
Artikel bewerten:
(1)

Pharmacovigilance Market Size Worth USD 12.48 Billion by 2027 | CAGR of 12.5%: Emergen Research

- Increasing incidences of drug toxicity and ADR (adverse drug reactions) are stimulating the market demand.

- Market Size - USD 4,820.5 Million in 2019, Market Growth - CAGR of 12.5%, Market Trends -Rise in the development and consumption rate of drugs

VANCOUVER, BC, Oct. 8, 2020 /PRNewswire/ -- The Global Pharmacovigilance Market is estimated to be worth USD 12.48 Billion by 2027, according to a recent report by Emergen Research. The pharmacovigilance market is experiencing rapid growth attributed to a rise in its application in spontaneous reporting, electronic health record (EHR) mining, cohort event monitoring, and intensified adverse drug reaction (ADR) reporting, among others. Pharmacovigilance primarily emphasizes on ADR (adverse drug reactions) and cases of drug toxicity. According to statistics released by WHO, about 5.0% of hospitalized patients in developed nations are admitted to the hospital due to adverse drug reactions, and 6.0 to 10% of in-patients are likely to observe a severe adverse reaction for the duration of hospitalization.

Emergen Research Logo

A rise in demand for outsourcing services by players in the healthcare industry is anticipated to boost the forecast period's pharmacovigilance market growth. A spiraling inclination to outsource eliminates the issues pertaining to overhead costs and the pharmacovigilance resources' deployment. Outsourcing is beneficial in enhancing the cost-effectiveness and output efficiency by releasing pressure associated with the procurement of resources on firms, therefore encouraging market growth. Leading pharmaceutical firms are substantially involved in extensive R&D ingenuities for novel therapeutic drug molecules to get superior outcomes, thereby successfully leading to a rise in drug development activities.

Request free sample of this research report at: https://www.emergenresearch.com/request-sample/81

Key Highlights from The Report

  • In December 2019, UCB and Accenture made an announcement about the signing of a partnership agreement to build a safety solution on INTIENT pharmacovigilance, by Accenture, to accelerate patient safety case reports' processing. The agreement is intended to help UCB in discovering the influence of existing treatments on patient safety, thereby managing the novel drugs' risk in a better way.
  • Spontaneous reporting is crucial in pharmacovigilance, providing information from real clinical settings in the course of a drug's life. Physicians and many other healthcare specialists contribute immensely to improving public health by supposed adverse drug reactions' reporting.
  • Several firms support in-house reporting management to healthcare authorities, as in-house reporting is possibly the major contact entity for any kind of in and out deliberation.
  • The escalating sophistication of biologics & therapeutic agents and the growing deployment of novel agents makes it essential to identify any undesired and unforeseen adverse effects and other toxicities as early as possible. Popular instances associated with the withdrawal of a drug from the market after receiving sanction verify Phase IV pharmacovigilance requirement.
  • Hospital pharmacists are indispensable in reporting adverse drug reactions, as many adverse drug events occur in hospitals, with adverse drug reactions being accountable for a substantial proportion of hospitalizations.
  • The APAC region's pharmacovigilance market is anticipated to have the fastest CAGR of 13.7% in the period 2020-2027, due to strict legislative regulations for ADR reporting and several firms offering pharmacovigilance outsourcing services. Besides, increased clinical trials' funding is causative of driving pharmacovigilance market demand in the region.
  • Key players in the market include Accenture, ArisGlobal, BoClinica Inc., Capgemini, IBM Corporation, IQVIA, Linical Accelovance, Cognizant, Laboratory Corporation of America Holdings, and ITClinical, among others.

To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/pharmacovigilance-market

Emergen Research has segmented the Global Pharmacovigilance Market on the basis of type, service provider, clinical trial phase, end-users, and region:

Type Outlook (Revenue, USD Million; 2017-2027)

  • Cohort Event Monitoring
  • Spontaneous Reporting
  • Targeted Spontaneous Reporting
  • Intensified Adverse Drug Reaction (ADR) Reporting
  • Electronic Health Record (HER) Mining

Service Provider Outlook (Revenue, USD Million; 2017-2027)

  • Contract Outsourcing
  • In-House

Clinical Trial Phase Outlook (Revenue, USD Million; 2017-2027)

  • Pre-Clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

End-Users Outlook (Revenue, USD Million; 2017-2027)

  • Hospitals
  • Research Organizations
  • Others

Regional Outlook (Revenue, USD Billion; 2017-2027)

- North America

  1. U.S.
  2. Canada

- Europe

  1. Germany
  2. U.K.
  3. France
  4. Benelux
  5. Rest of Europe

- Asia Pacific

  1. China
  2. Japan
  3. South Korea
  4. Rest of APAC

- Latin America

  1. Brazil
  2. Rest of LATAM

- Middle East & Africa

  1. Saudi Arabia
  2. UAE
  3. Rest of MEA

Find more similar research insights by Emergen Research:

Computational Biology Market By Service-Type (In-House, Contract), By Application (Cellular & Biology Simulation, Drug discovery and disease modeling, Pre-clinical drug development), By End-Use (Academics, Industry, Commercial), and By Region, and By Region, Forecasts to 2027

Medical Cannabis Market By Product Type (Oil, Buds, Tinctures), By Application (Chronic Pain, Mental Disorders, Anorexia, Seizures, Muscle Spasm, Cancer, Others), By Route of Administration, By Distribution Channel, and By Region, Forecasts to 2027

Diabetic Care Market By Devices (Monitoring Devices, Insulin Pumps, Syringes and Cartridges, Disposable Pens, Jet Injectors), By Distribution Channel (Hospital, Retail and Online Pharmacies, Diabetic Clinics, Others), By End User (Hospitals, Homecare, Diagnostic Centers) and By Regions Forecasts to 2027

Cerebrospinal Fluid Management Market By Product (Critical Care Product, Shunts & Valves, Others), By Patient Type (Geriatric, Adult, Pediatric), By End-Use (Clinics, Hospitals, Ambulatory Surgical Centers, Others), By Region Forecasts to 2027

Breath Analyzers Market By Application (Alcohol, Drug abuse, Tuberculosis and Asthma detection, Others), By Technology (Fuel cell, Semiconductor Oxide Sensor, Infrared Spectroscopy, Chemical Crystal, Others) and By Regions Forecasts to 2027

Assistive Reproductive Technology Market By Procedure (Fresh Donor, Fresh Non-Donor, Frozen Donor, Frozen Non-Donor, Egg/Embryo Banking), By Technology (In-Vitro Fertilization (IVF)), By End-Users, Forecasts to 2027

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

With market-leading insights and an in-depth understanding of leading and niche technologies, our solutions address the most pertinent questions for your business needs. A major technological shift has been witnessed towards creating a 'Circular Economy,' fuelled by factors, such as the increased adoption of bio-based materials, along with other methods for achieving carbon neutrality. We are conversant in technologies, viz., Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR), Robotic Process Automation (RPA), Smart Manufacturing, Internet of Things (IoT), Big Data Analytics, Machine learning, Nanotechnology, Edge Computing, Blockchain Technology, Cloud Computing, Vehicle Electrification, Advanced Maintenance Analytics, and Predictive Maintenance, among other prevalent and emergent technologies.

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Read full Press Release at: https://www.emergenresearch.com/press-release/global-pharmacovigilance-market

Logo: https://mma.prnewswire.com/media/1252126/Emergen_Research_Logo.jpg

© 2020 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.